Inozyme Pharma Stock Price To Earnings To Growth
| INZY Stock | USD 2.81 0.12 4.46% |
Inozyme Pharma fundamentals help investors to digest information that contributes to Inozyme Pharma's financial success or failures. It also enables traders to predict the movement of Inozyme Stock. The fundamental analysis module provides a way to measure Inozyme Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inozyme Pharma stock.
Inozyme | Price To Earnings To Growth |
Inozyme Pharma Company Price To Earnings To Growth Analysis
Inozyme Pharma's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Inozyme Pharma Price To Earnings To Growth | (0.06) X |
Most of Inozyme Pharma's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inozyme Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Inozyme Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Inozyme Pharma is extremely important. It helps to project a fair market value of Inozyme Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Inozyme Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inozyme Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inozyme Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Inozyme Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Inozyme Pharma has a Price To Earnings To Growth of -0.06 times. This is 108.45% lower than that of the Biotechnology sector and 101.91% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 101.23% higher than that of the company.
Inozyme Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inozyme Pharma's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics of similar companies.Inozyme Pharma is currently under evaluation in price to earnings to growth category among its peers.
Inozyme Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inozyme Pharma from analyzing Inozyme Pharma's financial statements. These drivers represent accounts that assess Inozyme Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inozyme Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 265.9M | 482.7M | 160.7M | 39.7M | 220.8M | 263.1M | |
| Enterprise Value | 234.3M | 324.1M | 140.7M | 13.5M | 232.8M | 215.4M |
Inozyme Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inozyme Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inozyme Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Inozyme Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 95.7 M | ||||
| Shares Outstanding | 64.24 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 96.67 % | ||||
| Number Of Shares Shorted | 3.23 M | ||||
| Price To Book | 2.18 X | ||||
| EBITDA | (74.81 M) | ||||
| Net Income | (71.17 M) | ||||
| Cash And Equivalents | 151.48 M | ||||
| Cash Per Share | 3.77 X | ||||
| Total Debt | 46.59 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.54 X | ||||
| Book Value Per Share | 1.29 X | ||||
| Cash Flow From Operations | (70.67 M) | ||||
| Short Ratio | 14.61 X | ||||
| Earnings Per Share | (1.55) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 18.75 | ||||
| Number Of Employees | 59 | ||||
| Beta | 1.54 | ||||
| Market Capitalization | 180.51 M | ||||
| Total Asset | 200.85 M | ||||
| Retained Earnings | (285.93 M) | ||||
| Working Capital | 181.56 M | ||||
| Net Asset | 200.85 M |
About Inozyme Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.